Efficacy Comparison of Ursodeoxycholic Acid and Hydroxymethylnicotinamide in the Treatment of Chronic Hepatitis B Complicating with Intrahepatic Cholestasis

OBJECTIVE: To observe therapeutic efficacy of ursodeoxycholic acid and hydroxymethylnicotinamide in the treatment of chronic cholestatic hepatitis B. METHODS: In this trial, 96 patients with chronic cholestatic hepatitis B were randomly divided into ursodeoxycholic acid group(n=56) and hydroxymethylnicotinamide group(n=40). Ursodeoxycholic acid group received ursodeoxycholic acid for 4 weeks, and hydroxymethylnicotin group received hydroxymethylnicotinamide for 4 weeks. Clinical efficacy was evaluated two-week and four-week after treatment. RESULTS: After two-week treatment, the indicators of liver function had improved in both groups, but there was no statistical difference in the reduction of total bilirubin, bilirubin direct and placental alkaline phosphatase between 2 groups (P0.05). After four-week treatment, the decrease of liver function indicators in ursodeoxycholic acid group were more significant than in hydroxymethylnicotin group, there was statistical significance (P0.05). Effective rate of ursodeoxycholic acid group was significantly higher than that of hydroxymethylnicotin group(75% vs. 70%, P=0.02).CONCLUSION: Ursodeoxycholic acid has better efficacy than hydroxymethylnicotinamide in the treatment of chronic hepatitis B complicating with intrahepatic cholestasis.